- Home
- DMAC vs BRW Comparison
DMAC vs BRW Comparison
Compare DMAC & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- BRW
- Stock Information
- Founded
- DMAC 2000
- BRW 1987
- Country
- DMAC United States
- BRW United States
- Employees
- DMAC N/A
- BRW N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- BRW Trusts Except Educational Religious and Charitable
- Sector
- DMAC Health Care
- BRW Finance
- Exchange
- DMAC Nasdaq
- BRW Nasdaq
- Market Cap
- DMAC 310.1M
- BRW 355.1M
- IPO Year
- DMAC N/A
- BRW N/A
- Fundamental
- Price
- DMAC $6.70
- BRW $7.29
- Analyst Decision
- DMAC Strong Buy
- BRW
- Analyst Count
- DMAC 3
- BRW 0
- Target Price
- DMAC $12.33
- BRW N/A
- AVG Volume (30 Days)
- DMAC 256.1K
- BRW 222.1K
- Earning Date
- DMAC 11-12-2025
- BRW 01-01-0001
- Dividend Yield
- DMAC N/A
- BRW 15.59%
- EPS Growth
- DMAC N/A
- BRW N/A
- EPS
- DMAC N/A
- BRW N/A
- Revenue
- DMAC N/A
- BRW N/A
- Revenue This Year
- DMAC N/A
- BRW N/A
- Revenue Next Year
- DMAC N/A
- BRW N/A
- P/E Ratio
- DMAC N/A
- BRW N/A
- Revenue Growth
- DMAC N/A
- BRW N/A
- 52 Week Low
- DMAC $3.19
- BRW $7.15
- 52 Week High
- DMAC $7.49
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- DMAC 48.84
- BRW 34.28
- Support Level
- DMAC $6.50
- BRW $7.25
- Resistance Level
- DMAC $7.10
- BRW $7.40
- Average True Range (ATR)
- DMAC 0.29
- BRW 0.10
- MACD
- DMAC -0.03
- BRW 0.01
- Stochastic Oscillator
- DMAC 32.90
- BRW 7.24
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.